| Date Filed | Type | Description |
| 06/05/2023 |
4
| Harris Erik (Director) has filed a Form 4 on Denali Therapeutics Inc.|
Txns:
| Granted 4,216 shares
@ $0
Granted 12,649 options to buy
@ $30.92, valued at
$391.1k
|
|
| 03/03/2023 |
4
| Harris Erik (EVP & Chief Commercial Officer) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.|
Txns:
| Granted 2,663 shares
@ $0
Granted 22,000 shares
@ $0
Sold 3,664 shares
@ $45.25, valued at
$165.8k
Granted 39,400 options to buy
@ $45.65, valued at
$1.8M
|
|
| 06/22/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/03/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/14/2022 |
3/A
| Harris Erik (Director) has filed a Form 3/A on Denali Therapeutics Inc. |
| 02/07/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/07/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 10/18/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/08/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/23/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/10/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/21/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/03/2021 |
4
| Harris Erik (EVP & Chief Commercial Officer) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.|
Txns:
| Granted 5,500 shares
@ $0
Granted 4,636 shares
@ $0
Sold 2,470 shares
@ $138.17, valued at
$341.3k
Sold 707 shares
@ $138.16, valued at
$97.7k
Granted 11,000 options to buy
@ $142.47, valued at
$1.6M
|
|
| 02/03/2021 |
4
| Harris Erik (EVP & Chief Commercial Officer) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.|
Txns:
| Sold 2,516 shares
@ $74.69, valued at
$187.9k
|
|
| 10/16/2020 |
4
| Harris Erik (EVP & Chief Commercial Officer) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.|
Txns:
| Sold 220 shares
@ $88, valued at
$19.4k
|
|
| 07/08/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/22/2020 |
4
| Harris Erik (EVP & Chief Commercial Officer) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.|
Txns:
| Paid exercise price by delivering 303 shares
@ $78.22, valued at
$23.7k
|
|
| 05/08/2020 |
4
| Harris Erik (EVP & Chief Commercial Officer) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.|
Txns:
| Paid exercise price by delivering 209 shares
@ $66.26, valued at
$13.8k
|
|
| 04/21/2020 |
4
| Harris Erik (EVP & Chief Commercial Officer) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.|
Txns:
| Paid exercise price by delivering 210 shares
@ $58.57, valued at
$12.3k
|
|
| 03/03/2020 |
4
| Harris Erik (EVP & Chief Commercial Officer) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.|
Txns:
| Granted 7,800 shares
@ $0
Granted 3,287 shares
@ $0
Paid exercise price by delivering 824 shares
@ $56.08, valued at
$46.2k
Granted 22,000 options to buy
@ $56.08, valued at
$1.2M
|
|
| 10/16/2019 |
4
| Harris Erik (EVP & Chief Commercial Officer) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.|
Txns:
| Granted 1,208 shares
@ $0 |
|
| 07/09/2019 |
4
| Harris Erik (EVP & Chief Commercial Officer) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.|
Txns:
| Paid exercise price by delivering 260 shares
@ $59.51, valued at
$15.5k
|
|
| 06/21/2019 |
4
| Harris Erik (EVP & Chief Commercial Officer) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.|
Txns:
| Granted 3,500 shares
@ $0
Granted 12,000 options to buy
@ $63.27, valued at
$759.2k
|
|
| 06/21/2019 |
3
| Harris Erik (EVP & Chief Commercial Officer) has filed a Form 3 on Ultragenyx Pharmaceutical Inc. |